


CASE REPORT

Open Access



Primary omental smooth muscle tumor in an adult male: a diagnostic dilemma for leiomyoma: a case report

Yukari Ono^{1,2}, Yoichiro Okubo^{1*} , Kota Washimi¹, Yo Mikayama², Tsunehiro Doiuch³, Chie Hasegawa¹, Emi Yoshioka¹, Kyoko Ono¹, Manabu Shiozawa¹ and Tomoyuki Yokose¹

Abstract

Background The greater omentum comprises peritoneal, adipose, vascular, and lymphoid tissues. Most omental malignancies are metastatic tumors, and the incidence of primary tumors is rare. We report on a prior omental smooth muscle tumor case in an adult male patient.

Case presentation A 54-year-old Japanese male patient with no relevant medical history was diagnosed with an abdominal mass during a routine medical checkup. Subsequent contrast-enhanced computed tomography revealed a mass of approximately 3 cm in size in the greater omentum, and a laparotomy was performed. A 27 × 25 × 20 mm raised lesion was found in the omentum. Microscopically, spindle cells were observed and arranged in whorls and fascicles. Individual tumor cells had short spindle-shaped nuclei with slightly increased chromatin and were characterized by a slightly eosinophilic, spindle-shaped cytoplasm. The mitotic count was less than 1 per 50 high-power fields. The tumor cells showed positive immunoreactivity for a smooth muscle actin, HHF35, and desmin on immunohistochemical examination. The Ki-67 labeling index using the average method was 1.76% (261/14806). No immunoreactivity was observed for any of the other tested markers. We considered leiomyoma owing to a lack of malignant findings. However, primary omental leiomyoma has rarely been reported, and it can be difficult to completely rule out the malignant potential of smooth muscle tumors in soft tissues. Our patient was decisively diagnosed with a primary omental smooth muscle tumor considering leiomyoma. Consequently, the patient did not undergo additional adjuvant therapy and was followed up. The patient was satisfied with treatment and showed neither recurrence nor metastasis at the 13-month postoperative follow-up.

Discussion and conclusion We encountered a primary smooth muscle tumor of the greater omentum with no histological findings suggestive of malignancy in an adult male patient. However, omental smooth muscle tumors are extremely difficult to define as benign, requiring careful diagnosis. Further case reports with long-term follow-up and case series are required to determine whether a true omental benign smooth muscle tumor (leiomyoma) exists. In addition, proper interpretation of the Ki-67 labeling index should be established. This case study is a foundation for future research.

Keywords Omentum, Leiomyoma, Smooth muscle tumor, Ki-67 labeling index, Case report

*Correspondence:

Yoichiro Okubo

yoichiro0207@hotmail.com

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

The greater omentum is a two-layered membrane that arises from the greater curvature of the stomach, extends down to cover the abdominal organs, and folds back to join the transverse colon [1]. This organ mainly comprises the peritoneal and adipose tissues and includes vessels and lymphoid tissue [2, 3]. The greater omentum contains omentum-associated lymphoid tissues (OALTs), also called “milky spots” [2]. OALT promptly filters lymphocytes, including various types of cells, and is responsible for the immune defense in the abdominal cavity [4]. Notably, OALT has a significant impact on peritoneal carcinomatosis because it is also responsible for tumor cell filtration [4–6]. Therefore, most malignancies of the greater omentum are metastatic, and the incidence of primary tumors is rare [1, 7]. Herein, we report a case of a primary smooth muscle tumor arising in the greater omentum in an adult male, along with its histological characteristics. The tumor was challenging to definitively diagnose as leiomyoma.

Case presentation

The patient was a 54-year-old Japanese male with no medical treatment history. However, an abdominal ultrasound performed during a routine medical checkup incidentally detected a solid mass in the abdominal cavity. The patient was referred to the medium-scale hospital for a more detailed examination, and contrast-enhanced computed tomography (CT) was performed. The results showed an abdominal mass approximately 3 cm in size in the greater omentum, near the posterior wall of the stomach and transverse colon. Subsequently, the patient was referred to the department of gastrointestinal surgery at our hospital for further examination to obtain a definitive diagnosis.

Results of a detailed examination at our hospital revealed that the patient, working as an office employee, had no significant medical or surgical history. He smoked 20 cigarettes daily since age 20 years and consumed 250 mL of beer daily. The family history was significant for cancer, with his father diagnosed with rectal cancer at age 65 years, his mother with breast cancer at 60 years, and his maternal grandmother with pancreatic cancer at 55 years. Upon physical examination, the patient was asymptomatic with no abnormal physical or neurological findings. Vital signs were within normal limits. Laboratory investigations revealed a normal complete blood count, with white blood cells at 7000/ μL , red blood cells at 4.69 million/ μL , platelets at 28.1×10^3 / μL , and hemoglobin at 15.8 g/dL. Renal function tests were within normal limits, with creatinine at 0.77 mg/dL and blood urea nitrogen at 11 mg/

dL. Electrolyte levels were stable, with sodium (Na) at 141 mmol/L, chloride (Cl) at 105 mmol/L, potassium (K) at 4.3 mmol/L, and calcium (Ca) at 9.5 mg/dL. Liver enzymes, including aspartate aminotransferase at 19 U/L, alanine aminotransferase at 18 U/L, gamma-glutamyl transferase at 61 U/L, albumin at 4.5 g/dL, total protein at 7 g/dL, and total bilirubin at 1 mg/dL, were within normal ranges. Inflammatory markers were low, with C-reactive protein at 0.06 mg/dL; hemoglobin A1c was 5.3%, indicating no evidence of diabetes. Regarding the patient’s medication history, there were no medications being taken prior to the diagnosis, and notably, the patient had not undergone any form of chemotherapy before or after surgery. No medications were administered prior to diagnosis, with attention focused on diagnostic assessments and surgical intervention for the primary omental smooth muscle tumor. The patient’s history did not suggest any environmental or occupational exposures contributing to his condition. The case was meticulously documented, considering the detailed family history of cancer and the patient’s lifestyle habits, such as smoking and alcohol consumption, to provide a comprehensive background for diagnosis and management.

The patient had no specific symptoms, such as abdominal pain, and no ascites or other lesions were detected on whole body evaluation. Contrast-enhanced CT at our hospital also demonstrated a 3 cm in size solitary mass in the omentum (Fig. 1). Open laparotomy was eventually performed because malignancy could not be ruled out clinically, and a needle biopsy could have caused tumor dissemination. The intraoperative findings were a solitary tumor within the omentum, with no evidence of adhesion to the adjacent posterior wall of the stomach or transverse colon.




Fig. 1 Representative contrast-enhanced computed tomography images in this case. A contrast-enhanced computed tomography scan showing an abdominal mass approximately 3 cm in size in the greater omentum (arrow indicates tumor)

Macroscopically, the specimen after formalin fixation was a 27 mm × 25 mm × 20 mm elevated lesion with slight adipose tissue in the periphery. Solid tumors with heterogeneous grayish-white cut surfaces were observed, and no obvious calcification or necrosis was observed (Fig. 2). Microscopically, spindle cells were observed and arranged in whorls and fascicles. Individual tumor cells

had short spindle-shaped nuclei with a slight increase in chromatin, and a slightly eosinophilic, spindle-shaped cytoplasm was observed. No hyalinization, calcification, or tumor necrosis was observed in the background. The mitotic count was less than 1 per 50 high-power fields. Furthermore, no abundance of blood vessels were observed to suggest angioleiomyoma (Fig. 3).




Fig. 2 Macroscopic findings of the tumor. **A** Formalin fixation showing that macroscopically, the specimen is a 27 mm × 25 mm × 20 mm elevated lesion with slight adipose tissue in the periphery. The surface is somewhat rough, but no obvious capsular rupture or tumor exposure is observed. **B** A solid tumor, which is grayish-white and heterogeneous, is observed on the cut surface. Although the general appearance is elastic and slightly firm, no obvious calcification or necrosis is observed




Fig. 3 Microscopic findings at various magnifications in this tumor. **A, B** Low-power-field view. Tumor cells are arranged in whorls and fascicles. Hyalinization or necrosis is not observed. In addition, adipose tissue is adherent to the periphery, but no obvious irregularities are detected (hematoxylin and eosin staining, magnification ×20). **C** Medium-power field view of the case. The tumor cells arranged in the whorls and fascicles are clarified. Abundant blood vessels suggestive of angioleiomyoma are not observed. In addition, neither nuclear atypia nor mitotic figures, recognizable at this magnification, could be detected (hematoxylin and eosin staining, magnification ×100). **D** High-power field view of the patient. Individual tumor cells had short spindle-shaped nuclei with a slight increase in chromatin and slightly eosinophilic, spindle-shaped cytoplasm (hematoxylin and eosin staining, magnification ×400)

On immunohistochemical examination, tumor cells showed positive immunoreactivity focally to α SMA and diffusely to HHF35 and desmin (Fig. 4). The Ki-67 labeling index was 1.76% (261/14806) using the average method, while it was 3.51% (43/1226) using the hot-spot method [8, 9]. We counted the Ki-67 labeling index using the “Pathoscope” analysis software (MITANI Corporation, Japan, URL: http://www.mitani-visual.jp/en/products/bio_imaging_analysis/pathoscope/), as previously described [10, 11]. Meanwhile, the tumor cells showed negative immunoreactivity for CD34, c-kit, DOG-1, STAT6, S100, HMB45, Melan A, CDK4, MDM2, β -catenin, calretinin, WT-1, estrogen receptor, and progesterone receptor (Fig. 5). In addition, Epstein–Barr virus-encoded RNA in situ hybridization (EBER ISH) showed negative signals in all tumor cells.

Immunohistochemical examination was performed, and no findings suggestive of malignancy (e.g., irregular nuclear shape, mitotic figures, and tumor necrosis) were noted. The results showed smooth muscle marker expression (positive immunoreactivity for α SMA, HHF35, and desmin). In addition, no findings indicating other histological types were found; thus, leiomyoma was considered. However, primary omentum leiomyomas have

rarely been reported, except for parasitic leiomyomas [3, 12]. It is also sometimes difficult to completely rule out the malignant potential in smooth muscle tumors in deep soft tissue [13, 14], even in tumors without nuclear atypia, mitotic figures, and coagulopathic tumor necrosis [15].

Therefore, the patient was finally diagnosed with a primary omental smooth muscle tumor considering leiomyoma. The patient consequently did not undergo additional adjuvant therapy and was followed up. Neither recurrence nor metastasis was found on the 13-month postoperative follow-up.

Discussion and conclusion

We report the case of a primary omental smooth muscle tumor that histologically showed no definite malignant findings in an adult male patient. Except for parasitic leiomyoma, primary omental smooth muscle tumors [16] are extremely rare, and only a few cases have been reported [3, 12]. Tumors arising from the deep soft tissue mainly occur in middle-aged adults with no sex predilection [15]. Histological assessment using imaging is typically difficult, and detailed histological analysis is important for diagnosis [15, 17,




Fig. 4 Representative images showing immunoreactivity in the tumor. **A–C** On immunohistochemical examination, tumor cells show positive immunoreactivity focally to α SMA (**A**) and diffusely to HHF 35 and desmin (**C** and **D**, respectively). **D** Only a few Ki-67 positive cells are observed. According to the image analysis software, the Ki-67 labeling index using the average method is 1.76% (261/14806), while it is 3.51% (43/1226) using the hot-spot method (**A** α SMA, **B** HHF35, **C** desmin, **D** Ki-67, $\times 100$)




Fig. 5 Representative images showing no immunoreactivity in this tumor. **A–D** Tumor cells show no immunoreactivity to c-kit, STAT6, HMB45, and CDK4. STAT6 is faintly positive in the cytoplasm but not in the nucleus and is, thus, determined to be negative (**A** c-kit, **B** STAT6, **C** HMB45, **D** CDK4; magnification for **A**, **C**, and **D** $\times 100$ and for **B** $\times 200$)

18]. The diagnostic criteria for primary leiomyomas from deep soft tissues are stringent [14]. The diagnosis should be made only after compliance with the following criteria: no nuclear atypia, no or few mitotic figures, and no coagulopathic tumor necrosis on the whole specimen [14].

However, it is difficult to completely rule out the malignant potential in deep soft tissue smooth muscle tumors, even in cases that meet these criteria, and the possibility of a definitive diagnosis of leiomyoma remains controversial [19]. The Ki-67 labeling index is widely known as an indicator of proliferative activity of tumors [20–23], and the average is reported to be $0.52 \pm 1.32\%$ [mean \pm standard deviation (SD)] in extrauterine leiomyomas [24]. The Ki-67 labeling index using the average method of the current case is within the mean \pm SD range of a previous study, but it is close to the upper limit of the mean value plus one SD of the value [24]. Moreover, the Ki-67 labeling index using the hot spot method is 3.5%, which exceeds the mean value plus one SD. If the value is significantly high, leiomyosarcoma can be considered. Nevertheless, if the value is questionable, there are no clear criteria for interpreting the Ki-67 labeling index of smooth muscle tumors arising from deep soft tissue. Therefore, the validity of the hotspot method, the number

of tumor cells counted, and the appropriate method for determining the cutoff value remain controversial.

The hotspot method, widely applied to neuroendocrine tumors, might be reasonable [25, 26]. Further analysis is required to define the number of cells counted and cutoff values. There are also smooth muscle tumors of uncertain malignant potential [14, 15, 27, 28]. However, it is unclear whether it can be considered in all cases arising from deep soft tissue, even in cases with no findings indicating malignancy. Therefore, further case reports with long-term follow-up and case series are required to determine whether a true omental benign smooth muscle tumor (leiomyoma) exists. While the current patient was male and we did not necessarily consider a parasitic leiomyoma (an ectopic leiomyoma that arises separately from the uterus), parasitic leiomyoma should be considered in female patients [29]. It is important to confirm the absence of a history of laparoscopic leiomyomectomy or hysterectomy [30]. In some cases, Epstein–Barr virus (EBV)-associated smooth muscle tumor is also a differential diagnosis. In the present case, EBER ISH showed negative signals [31].

We also shed some light on the differential diagnosis from the perspective of spindle cell tumors with relatively little atypia, considering the omental primary. The

following types of tumors should be considered: gastrointestinal stromal tumor (GIST), solitary fibrous tumor (SFT), schwannoma, perivascular epithelioid cell tumor (PEComa), and a sclerosing variant of well-differentiated liposarcoma. Extra-GISTs are rare, but several cases have been reported [32–36]. Tumors in the greater omentum are frequently diagnosed as GIST [34]. Immunostaining for CD34 and c-kit can be helpful, but because approximately 5% of the cases show negative results, positivity for other GIST marker expressions, including DOG-1, should also be confirmed [37].

Notably, even GIST rarely shows immunoreactivity to desmin; therefore, other smooth muscle markers should also be evaluated [38]. The presence of a patternless pattern and CD34 immunoreactivity are traditionally common in SFT [39], and the immunoreactivity of STAT6 has recently been emphasized [40, 41]. In addition, smooth muscle markers are negative [42], which is a point of differentiation. Schwannomas often have a morphological mixture of high cell density (Antoni type A) and low cell density (Antoni type B) [43]. Tumor cells show regular- and spindle-shaped nuclei with wavy cytoplasm. Typically, this tumor shows diffuse S100 immunoreactivity and can be differentiated by its negative immunoreactivity for smooth muscle markers [44]. PEComa consists of a mixture of spindle smooth muscle tissue, as well as various types of blood vessels and adipose tissue. However, the proportion of these cells varies among cases, and wholly spindle-shaped tumor cells have been reported [45]. Therefore, it is important to confirm the immunoreactivity of markers, such as HMB45 and Melan A [28, 46].

The sclerosing variant of well-differentiated liposarcoma is extremely rare, but it is a morphological differential disease owing to the lack of fatty components and nuclear atypia [47]. The presence of typical lipoblasts or atypical stromal cells in the surrounding adipose tissue, confirmation of markers, such as CDK4, MDM2, and p16 [48], and negative smooth muscle marker expression are the distinguishing characteristics. Furthermore, confirmation of MDM2 gene amplification by fluorescent *in situ* hybridization is helpful if immunostaining is unsuccessful [49].

We encountered an extremely rare case of primary smooth muscle tumor of the greater omentum in an adult male patient with no histological findings suggestive of malignancy. However, omental smooth muscle tumors are extremely difficult to define as benign; therefore, further case reports with long-term follow-up and case series are required in the future to determine whether a true omental benign smooth muscle tumor (leiomyoma) exists. In addition, proper interpretation of the Ki-67 labeling index should be established

(i.e., the validity of the hotspot method, the number of tumor cells to be counted, and the appropriate method to determine the cutoff value). We report this case to emphasize that this tumor requires careful diagnosis and hope that this will act as a foundation for future research.

Abbreviations

OALT	Omentum-associated lymphoid tissues
CT	Computed tomography
EBER ISH	Epstein–Barr virus-encoded RNA in situ hybridization
SD	Standard deviation
GIST	Gastrointestinal stromal tumor
SFT	Solitary fibrous tumor
PEComa	Perivascular epithelioid cell tumor

Acknowledgements

The authors thank Mitsuyo Yoshihara for excellent technical support. The authors would also like to thank Editage (www.editage.jp) for the language editing.

Author contributions

YO (first author) integrated the data and literature and wrote the manuscript as the first author; YO (second and corresponding author) integrated data and literature with the first author and revised the manuscript; KW, as an expert in soft tissue tumors, discussed the pathological findings and provided appropriate information; YM operated on this case as a surgeon and provided clinical findings, including practical surgical findings, to the first and corresponding authors; TD provided information on radiological findings in detail; CH, EY, and KO advised the first and corresponding authors on pathological findings of this case as pathologists and partially revised the manuscript; MS operated on this case together with YM, and also provided detailed preoperative and postoperative clinical findings to the first and lead authors as chief of surgery; TY, as chief of pathology, provided the first and corresponding authors with the findings for smooth muscle tumors and differential diagnosis and revised the manuscript.

Funding

This work was supported by JSPS KAKENHI (grant number 17K08713 to YO) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the Kanagawa Cancer Center and Research Institute/Kanagawa Prefectural Institute Organization (grant number 2023-1 and 2023-gankikin to YO).

Availability of data and materials

The dataset supporting the conclusions of this study is included within the article, and all materials are available upon reasonable request.

Declarations

Ethics approval and consent to participate

This study was performed in accordance with the Declaration of Helsinki and written informed consent was taken from the patient and patient specific information is de-identified.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Pathology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-Ku, Yokohama, Kanagawa 241-8515, Japan. ²Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-Ku, Yokohama, Kanagawa 241-8515, Japan. ³Department of Diagnostic and Interventional Radiology,

Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-Ku, Yokohama, Kanagawa 241-8515, Japan.

Received: 14 November 2023 Accepted: 2 April 2024

Published online: 05 May 2024

References

1. Branes A, Bustamante C, Valbuena J, Pimentel F, Quezada N. Primary leiomyosarcoma of the greater omentum: a case report. *Int J Surg Case Rep.* 2016;28:317–20. <https://doi.org/10.1016/j.ijscr.2016.10.025>.
2. Shimotsuma M, Shirasu M, Hagiwara A, Takahashi T. Role of omentum-associated lymphoid tissue in the progression of peritoneal carcinomatosis. *Cancer Treat Res.* 1996;82:147–54. https://doi.org/10.1007/978-1-4613-1247-5_9.
3. Bhandarkar D, Ghuge A, Kadakia G, Shah R. Laparoscopic excision of an omental leiomyoma with a giant cystic component. *JLS.* 2011;15(3):409–11. <https://doi.org/10.4293/10868081X13125733357232>.
4. Meza-Perez S, Randall TD. Immunological functions of the omentum. *Trends Immunol.* 2017;38(7):526–36. <https://doi.org/10.1016/j.it.2017.03.002>.
5. Sun F, Feng M, Guan W. Mechanisms of peritoneal dissemination in gastric cancer. *Oncol Lett.* 2017;14(6):6991–8. <https://doi.org/10.3892/ol.2017.149>.
6. Kanda M, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. *World J Gastroenterol.* 2016;22(30):6829–40. <https://doi.org/10.3748/wjg.v22.i30.6829>.
7. Ishida H, Ishida J. Primary tumours of the greater omentum. *Eur Radiol.* 1998;8(9):1598–601. <https://doi.org/10.1007/s003300050594>.
8. Jang MH, Kim HJ, Chung YR, Lee Y, Park SY. A comparison of Ki-67 counting methods in luminal breast cancer: the average method vs. the hot spot method. *PLoS ONE.* 2017;12(2): e0172031. <https://doi.org/10.1371/journal.pone.0172031>.
9. Okubo Y, Toda S, Sato S, Yoshioka E, Ono K, Hasegawa C, et al. Histological findings of thyroid cancer after lenvatinib therapy. *Histopathology.* 2023;83(4):657–63. <https://doi.org/10.1111/his.15013>.
10. Ida A, Okubo Y, Kasajima R, Washimi K, Sato S, Yoshioka E, et al. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: histological features for accurate diagnosis and toward future novel therapies. *Pathol Res Pract.* 2022;229: 153731. <https://doi.org/10.1016/j.prp.2021.153731>.
11. Okubo Y, Yamamoto Y, Terao H, Suzuki T, Koizumi M, Yoshioka E, et al. Significance of non-standardized magnetic resonance imaging abnormalities and subsequent targeted prostate cancer biopsy for pathologists: a retrospective observational study. *Pathol Res Pract.* 2022;240: 154188. <https://doi.org/10.1016/j.prp.2022.154188>.
12. Shukunami K, Kurokawa T, Nishijima K, Kotsuji F. Leiomyoma originating in the greater omentum. *Eur J Obstet Gynecol Reprod Biol.* 2005;119(2):257. <https://doi.org/10.1016/j.ejogrb.2004.07.018>.
13. Miettinen M. Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis. *Mod Pathol.* 2014;27(Suppl 1):S17–29. <https://doi.org/10.1038/modpathol.2013.178>.
14. Billings SD, Folpe AL, Weiss SW. Do leiomyomas of deep soft tissue exist? An analysis of highly differentiated smooth muscle tumors of deep soft tissue supporting two distinct subtypes. *Am J Surg Pathol.* 2001;25(9):1134–42. <https://doi.org/10.1097/0000478-200109000-00003>.
15. McCarthy AJ, Chetty R. Benign smooth muscle tumors (leiomyomas) of deep somatic soft tissue. *Sarcoma.* 2018;2018:2071394. <https://doi.org/10.1155/2018/2071394>.
16. Ekwunife CN, Chukwulebe AE, Nwabueze CF, Ukah CO. Leiomyoma of the greater omentum presenting with massive ascites. *Int J Surg Case Rep.* 2012;3(11):513–5. <https://doi.org/10.1016/j.ijscr.2012.06.008>.
17. Okubo Y, Toda S, Kadoya M, Sato S, Yoshioka E, Hasegawa C, et al. Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis. *Virchows Arch.* 2024. <https://doi.org/10.1007/s00428-024-03777-w>.
18. Washimi K, Hiroshima Y, Sato S, Ueno M, Kobayashi S, Yamamoto N, et al. Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. *Pathol Int.* 2024. <https://doi.org/10.1111/pin.13416>.
19. Fletcher CD, Kilpatrick SE, Mentzel T. The difficulty in predicting behavior of smooth-muscle tumors in deep soft tissue. *Am J Surg Pathol.* 1995;19(1):116–7. <https://doi.org/10.1097/0000478-199501000-00015>.
20. Okubo Y, Sato S, Osaka K, Yamamoto Y, Suzuki T, Ida A, et al. Clinicopathological analysis of the ISUP grade group and other parameters in prostate cancer: elucidation of mutual impact of the various parameters. *Front Oncol.* 2021;11: 695251. <https://doi.org/10.3389/fonc.2021.695251>.
21. Avallone G, Pellegrino V, Muscatello LV, Roccabianca P, Castellani G, Sala C, et al. Canine smooth muscle tumors: a clinicopathological study. *Vet Pathol.* 2022;59(2):244–55. <https://doi.org/10.1177/03009858211066862>.
22. Yamamoto A, Tateishi Y, Aikou S, Seto Y, Ushiku T. The first case of gastric leiomyosarcoma developed through malignant transformation of leiomyoma. *Pathol Int.* 2021;71(12):837–43. <https://doi.org/10.1111/pin.13165>.
23. Okubo Y, Sato S, Terao H, Yamamoto Y, Suzuki A, Hasegawa C, et al. Review of the developing landscape of prostate biopsy and its roles in prostate cancer diagnosis and treatment. *Arch Esp Urol.* 2023;76(9):633–42. <https://doi.org/10.56434/j.arch.esp.urol.20237609.78>.
24. Sen N, Demirkan NC, Colakoglu N, Duzcan SE. Are there any differences in the expression of hormonal receptors and proliferation markers between uterine and extrauterine leiomyomas? *Int J Surg Pathol.* 2008;16(1):43–7. <https://doi.org/10.1177/1066896907309576>.
25. Lea D, Gudlaugsson EG, Skaland I, Lillesand M, Soreide K, Soreide JA. Digital image analysis of the proliferation markers Ki67 and phosphohistone H3 in gastroenteropancreatic neuroendocrine neoplasms: accuracy of grading compared with routine manual hot spot evaluation of the Ki67 index. *Appl Immunohistochem Mol Morphol.* 2021;29(7):499–505. <https://doi.org/10.1097/PAI.0000000000000934>.
26. Kroneman TN, Voss JS, Lohse CM, Wu TT, Smyrk TC, Zhang L. Comparison of three Ki-67 index quantification methods and clinical significance in pancreatic neuroendocrine tumors. *Endocr Pathol.* 2015;26(3):255–62. <https://doi.org/10.1007/s12022-015-9379-2>.
27. Okubo Y, Sato S, Hasegawa C, Koizumi M, Suzuki T, Yamamoto Y, et al. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores. *Hum Pathol.* 2023;135:99–107. <https://doi.org/10.1016/j.humpath.2023.01.008>.
28. Okubo Y, Yamamoto Y, Sato S, Yoshioka E, Suzuki M, Washimi K, et al. Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution. *Virchows Arch.* 2022;480(5):979–87. <https://doi.org/10.1007/s00428-022-03272-0>.
29. Oindi FM, Mutiso SK, Obura T. Port site parasitic leiomyoma after laparoscopic myomectomy: a case report and review of the literature. *J Med Case Rep.* 2018;12(1):339. <https://doi.org/10.1186/s13256-018-1873-y>.
30. Huang PS, Chang WC, Huang SC. Iatrogenic parasitic myoma: a case report and review of the literature. *Taiwan J Obstet Gynecol.* 2014;53(3):392–6. <https://doi.org/10.1016/j.tjog.2013.11.007>.
31. Ehresman JS, Ahmed AK, Palsgrove DN, Pennington Z, Goodwin CR, Sciubba DM. Epstein–Barr virus-associated smooth muscle tumor involving the spine of an HIV-infected patient: case report and review of the literature. *J Clin Neurosci.* 2018;52:145–50. <https://doi.org/10.1016/j.jocn.2018.03.009>.
32. Sawaki A. Rare gastrointestinal stromal tumors (GIST): omentum and retroperitoneum. *Transl Gastroenterol Hepatol.* 2017;2:116. <https://doi.org/10.21037/tgh.2017.12.07>.
33. Akbulut S, Yavuz R, Otan E, Hatipoglu S. Pancreatic extragastrointestinal stromal tumor: a case report and comprehensive literature review. *World J Gastrointest Surg.* 2014;6(9):175–82. <https://doi.org/10.4240/wjgs.v6.i9.175>.
34. Phiza A, Gulpinder S, Simrandeep S, Sushma B. Primary mesenteric gastrointestinal stromal tumour with concomitant mesenteric tuberculosis: careful histopathology is essential. *Trop Dr.* 2022. <https://doi.org/10.1177/00494755221076947>.
35. Tan Y, Lu J, Lv L, Le M, Liu D. Current status of endoscopic submucosal tunnel dissection for treatment of superficial gastrointestinal neoplastic lesions. *Expert Rev Gastroenterol Hepatol.* 2020;14(6):453–62. <https://doi.org/10.1080/17474124.2020.1766967>.
36. Wang X, Chen YP, Chen SB. Esophageal mucoepidermoid carcinoma: a review of 58 cases. *Front Oncol.* 2022;12: 836352. <https://doi.org/10.3389/fonc.2022.836352>.

37. Guler B, Ozyilmaz F, Tokuc B, Can N, Tastekin E. Histopathological features of gastrointestinal stromal tumors and the contribution of DOG1 expression to the diagnosis. *Balkan Med J.* 2015;32(4):388–96. <https://doi.org/10.5152/balkanmedj.2015.15912>.
38. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). *Mod Pathol.* 2000;13(10):1134–42. <https://doi.org/10.1038/modpathol.3880210>.
39. Tsushimi T, Yagi T, Tomozawa N, Ohnishi H. Retroperitoneal solitary fibrous tumor of the pelvis with pollakiuria: a case report. *BMC Res Notes.* 2012;5:593. <https://doi.org/10.1186/1756-0500-5-593>.
40. Yoshida A, Tsuta K, Ohno M, Yoshida M, Narita Y, Kawai A, et al. STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. *Am J Surg Pathol.* 2014;38(4):552–9. <https://doi.org/10.1097/PAS.000000000000137>.
41. Okubo Y, Nukada S, Shibata Y, Osaka K, Yoshioka E, Suzuki M, et al. Primary solitary fibrous tumour of the prostate: a case report and literature review. *Malays J Pathol.* 2020;42(3):449–53.
42. Geramizadeh B, Marzban M, Churg A. Role of immunohistochemistry in the diagnosis of solitary fibrous tumor, a review. *Iran J Pathol.* 2016;11(3):195–203.
43. Hilton DA, Hanemann CO. Schwannomas and their pathogenesis. *Brain Pathol.* 2014;24(3):205–20. <https://doi.org/10.1111/bpa.12125>.
44. Yap RV, Santos AM, Roble VM 2nd. Large benign schwannoma of the greater omentum with synchronous cervical cancer: a case report. *Int J Surg Case Rep.* 2021;83: 105961. <https://doi.org/10.1016/j.ijscr.2021.105961>.
45. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. *Virchows Arch.* 2008;452(2):119–32. <https://doi.org/10.1007/s00428-007-0509-1>.
46. Valencia-Guerrero A, Pinto A, Anderson WJ, Trevisan G, Nucci MR, Hirsch MS. PNL2: a useful adjunct biomarker to HMB45 in the diagnosis of uterine perivascular epithelioid cell tumor (PEComa). *Int J Gynecol Pathol.* 2020;39(6):529–36. <https://doi.org/10.1097/PGP.0000000000000653>.
47. Laurino L, Furlanetto A, Orvieto E, Dei Tos AP. Well-differentiated liposarcoma (atypical lipomatous tumors). *Semin Diagn Pathol.* 2001;18(4):258–62.
48. Peng R, Chen H, Yang X, Zhang X, Zhang Z, He X, et al. A novel sclerosing atypical lipomatous tumor/well-differentiated liposarcoma in a 7-year-old girl: report of a case with molecular confirmation. *Hum Pathol.* 2018;71:41–6. <https://doi.org/10.1016/j.humpath.2017.06.015>.
49. Sugiyama K, Washimi K, Sato S, Hiruma T, Sakai M, Okubo Y, et al. Differential diagnosis of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma by cytological analysis. *Diagn Cytopathol.* 2022;50(3):112–22. <https://doi.org/10.1002/dc.24928>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.